A case study of 10 people who experienced tics in childhood and developed Parkinson’s disease as adults illustrates how the underlying mechanisms of both disorders might be more complex than hypothesized. Researchers looked at individuals whose tics continued after the onset of Parkinson’s symptoms and treatment. Most…
The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application for XS-411, a stem cell-based therapy developed by Xellsmart for Parkinson’s disease, clearing the way for a Phase 1 clinical trial. The company also received FDA approval for a similar stem cell therapy…
Serina Therapeutics will use $5 million in new funding to further develop SER-252 (POZ-apomorphine) as a treatment for advanced Parkinson’s disease, with a Phase 1 clinical study now expected by the end of the year. The company secured the financing from shareholders to support clinical testing of SER-252,…
Get regular updates to your inbox.
